Status:
COMPLETED
Role of Magnetic Resonance Imaging (MRI) Perfusion to Detect Disease in Prostate Carcinoma
Lead Sponsor:
University Health Network, Toronto
Collaborating Sponsors:
Princess Margaret Hospital, Canada
Conditions:
Prostatic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This is a pilot study of 50 patients to establish whether there is a potential role for MRI perfusion in the detection of locally recurrent or persistent prostate carcinoma after previous treatment wi...
Eligibility Criteria
Inclusion
- Previously have had radical radiotherapy for localised prostate cancer
- Due to undergo routine post-treatment prostatic biopsies
- Suitable for MRI scan
- Adequate renal function
- No previous reaction to gadolinium
- Able to give informed consent
- No recent prostate biopsy within 6 weeks of enrolment
- Performance status (Eastern Cooperative Oncology Group \[ECOG\]) 0 or 1
Exclusion
- Not suitable for MRI scan
- Previous reaction to gadolinium
- Impaired renal function
- Inability to give informed consent
Key Trial Info
Start Date :
May 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00230386
Start Date
May 1 2003
Last Update
July 14 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Network Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9